| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
(S)-Boc-nipecotic acid does not have specific pharmacological targets, as it is a biochemical reagent used in organic synthesis rather than a therapeutic agent. The Boc (tert-butoxycarbonyl) group serves as a protecting group for the amine functionality during peptide synthesis. The compound is used as a building block in the synthesis of various bioactive molecules.
|
|---|---|
| ln Vitro |
(S)-Boc-nipecotic acid is not evaluated for traditional biological activity, as it is a biochemical reagent used in organic synthesis rather than a pharmacologically active compound. Its utility is based on its chemical properties as a protected amino acid derivative. No specific in vitro activity data have been reported.
|
| ln Vivo |
(S)-Boc-nipecotic acid is not used for in vivo pharmacological evaluation. It is a biochemical reagent used in laboratory research for organic synthesis. The compound is not administered to animals for therapeutic purposes. Its applications are limited to chemical synthesis and medicinal chemistry research.
|
| Enzyme Assay |
(S)-Boc-nipecotic acid is not evaluated in traditional enzyme/receptor binding assays. The compound's purity and identity are confirmed by standard analytical methods including HPLC, NMR, and mass spectrometry. Purity is typically ≥95%. The compound is used as a building block in peptide synthesis and medicinal chemistry.
|
| Cell Assay |
(S)-Boc-nipecotic acid is not evaluated in traditional cellular assays, as it is a biochemical reagent used in organic synthesis rather than a cellular modulator. The compound may be used in the synthesis of molecules that are subsequently tested in cellular assays. However, the compound itself is not tested in cellular systems.
|
| Animal Protocol |
(S)-Boc-nipecotic acid is not used in in vivo animal experiments. It is a biochemical reagent used in laboratory research for organic synthesis. The compound is not administered to animals for pharmacological evaluation. Its applications are limited to chemical synthesis and medicinal chemistry research.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to (S)-Boc-nipecotic acid, as it is a biochemical reagent used in organic synthesis rather than a therapeutic agent. The compound has a molecular weight of 229.28 g/mol and a molecular formula of C₁₁H₁₉NO₄. Storage: powder at -20°C for 3 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
The toxicological profile of (S)-Boc-nipecotic acid has not been extensively documented, as it is a biochemical reagent used in research rather than a therapeutic agent. Standard laboratory safety precautions should be followed when handling this compound. The compound is not intended for human consumption.
|
| Additional Infomation |
(S)-Boc-nipecotic acid (CAS# 88495-54-9, molecular formula C₁₁H₁₉NO₄, molecular weight 229.28) is a biochemical reagent used in life science related research. Also known as (S)-1-Boc-piperidine-3-carboxylic acid. No clinical trials or regulatory approvals have been identified. Purity ≥99.76%.
|
| Molecular Formula |
C11H19NO4
|
|---|---|
| Molecular Weight |
229.27
|
| Exact Mass |
229.131
|
| CAS # |
88495-54-9
|
| PubChem CID |
6951168
|
| Appearance |
White to off-white solid powder
|
| Density |
1.164 g/cm3
|
| Boiling Point |
353.2ºC at 760 mmHg
|
| Melting Point |
159-162ºC(lit.)
|
| Flash Point |
167.4ºC
|
| Index of Refraction |
1.496
|
| LogP |
1.656
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
282
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(N1CCC[C@H](C(=O)O)C1)(=O)OC(C)(C)C
|
| InChi Key |
NXILIHONWRXHFA-QMMMGPOBSA-N
|
| InChi Code |
InChI=1S/C11H19NO4/c1-11(2,3)16-10(15)12-6-4-5-8(7-12)9(13)14/h8H,4-7H2,1-3H3,(H,13,14)/t8-/m0/s1
|
| Chemical Name |
(3S)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3617 mL | 21.8083 mL | 43.6167 mL | |
| 5 mM | 0.8723 mL | 4.3617 mL | 8.7233 mL | |
| 10 mM | 0.4362 mL | 2.1808 mL | 4.3617 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
